Paul L Berns's Net Worth
$52.5 Million
Who is Paul L Berns?
Paul L Berns has an estimated net worth of $52.5 Million. This is based on reported shares across multiple companies, which include Anacor Pharmaceuticals, Inc., Jazz Pharmaceuticals plc, EQRx, Inc., Menlo Therapeutics Inc., Unity Biotechnology, Inc., Cellectar Biosciences, Inc., XENOPORT INC, ALLOS THERAPEUTICS INC, Neumora Therapeutics, Inc., and BONE CARE INTERNATIONAL INC.
SEC CIK
Paul L Berns's CIK is 0001202769
Past Insider Trading and Trends
2015 was Paul L Berns's most active year for acquiring shares with 15 total transactions. Paul L Berns's most active month to acquire stocks was the month of July. 2015 was Paul L Berns's most active year for disposing of shares, totalling 29 transactions. Paul L Berns's most active month to dispose stocks was the month of February. 2014 saw Paul L Berns paying a total of $7,423,500.00 for 779,950 shares, this is the most they've acquired in one year. In 2016 Paul L Berns cashed out on 856,339 shares for a total of $25,590,187.08, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Anacor Pharmaceuticals, Inc. No price found
President and CEO
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -231.31K |
$99.25 | -$22,957,616.75 |
0
|
Jun 24
| |||
Form 4
| -14.00% | -37.50K |
$60.31 | -$2,261,615.49 | 230.31K |
Scheduled
|
Mar 22
| ||
Form 4
| +5.76% | 14.58K |
—
|
—
| 267.81K |
Feb 3
| |||
Form 4
| -0.99% | -2.53K |
$112.35 | -$284,581.99 | 252.23K |
Scheduled
|
Jan 4
| ||
Form 4
|
—
|
0
|
$63.63 | -$2,145,186.91 | 254.76K |
Scheduled
|
Dec 11
| ||
Form 4
|
—
|
0
|
$72.51 | -$2,692,887.88 | 254.76K |
Scheduled
|
Sep 15
| ||
Form 4
|
—
|
0
|
$71.90 | -$2,671,678.05 | 254.76K |
Scheduled
|
Aug 13
| ||
Form 4
| -17.81% | -55.00K |
$63.64 | -$3,181,820.49 | 253.76K |
Scheduled
|
Mar 20 - Apr 27
| ||
Form 4
| -10.83% | -37.50K |
$56.07 | -$2,102,643.75 | 308.76K |
Scheduled
|
Mar 19
| ||
Form 4
| +6.21% | 20.26K |
—
|
—
| 346.26K |
Feb 3
| |||
Form 4
| -7.14% | -25.00K |
$30.82 | -$770,505.00 | 325K |
Scheduled
|
Dec 26
| ||
Form 4
|
∞
| 350K |
$21.21 | $7,423,500.00 | 350K |
Mar 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 6
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
May 30
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Jazz Pharmaceuticals plc (JAZZ) Snapshot price: $124.71
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -14.89% | -1.45K |
$154.00 | -$223,300.00 | 8.29K |
Aug 5
| |||
Form 4
|
—
|
0
|
$150.42 | -$705,603.65 | 9.74K |
Scheduled
|
Nov 2 - Nov 4
| ||
Form 4
| +22.27% | 1.77K |
$125.87 | -$117,185.44 | 9.74K |
Aug 6 - Aug 7
| |||
Form 4
| +17.63% | 1.19K |
$135.65 | -$98,481.10 | 7.97K |
Aug 8 - Aug 9
| |||
Form 4
| +14.06% | 835 |
$176.61 | -$116,563.19 | 6.77K |
Aug 9 - Aug 10
| |||
Form 4
| +13.43% | 703 |
$142.37 | -$94,247.63 | 5.94K |
Aug 10 - Aug 11
| |||
Form 4
| -10.79% | -633.00 |
$136.45 | -$86,372.85 | 5.23K |
Aug 15
| |||
Form 4
| +30.32% | 1.36K |
—
|
—
| 5.87K |
Aug 11
| |||
Form 4/A
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| +10.02% | 509 |
$180.00 | -$144,177.51 | 5.59K |
Aug 7 - Aug 10
| |||
Form 4
| -21.40% | -1.09K |
$133.15 | -$144,734.05 | 3.99K |
Aug 12
| |||
Form 4
| +48.10% | 1.65K |
—
|
—
| 5.08K |
Aug 7
| |||
Form 4
| -23.78% | -1.07K |
$81.86 | -$87,590.20 | 3.43K |
Aug 13
| |||
Form 4
| +100.00% | 2.25K |
—
|
—
| 4.5K |
Aug 8
| |||
Form 4
|
∞
| 2.25K |
—
|
—
| 2.25K |
Aug 9
| |||
Form 4
| -100.00% | -39.20K |
$49.56 | -$1,942,752.00 |
0
|
Mar 9
| |||
Form 4
|
∞
| 39.2K |
—
|
—
| 39.2K |
Jan 18
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
Form 4
| -100.00% | -39.20K |
—
|
—
|
0
|
Jan 18
| |||
Form 4
|
∞
| 39.2K |
$31.28 | $70.00 | 39.2K |
Jan 11 - Jan 11
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Nov 4
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Mar 10
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Aug 25
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 4
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
EQRx, Inc. (EQRX) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| -100.00% | -627.00K |
—
|
—
|
0
|
Nov 9
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jan 1
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Sep 30
| |||
Form 4
|
∞
| 627K |
—
|
—
| 627K |
Dec 17
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Menlo Therapeutics Inc. (VYNE) Snapshot price: $2.145
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4/A
|
—
|
0
|
—
|
—
|
0
|
Jun 25
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Unity Biotechnology, Inc. (UBX) Snapshot price: $1.71
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 21
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 23
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 24
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 18
| |||
Form 4
|
—
|
0
|
—
|
—
|
0
|
Jun 20
| |||
Form 4
|
∞
| 3.26K |
—
|
—
| 3.26K |
May 7
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||